“Compared with the control group, the AUC was significantly increased by 52.0–85.1%, and the Cmax was significantly increased by 93.1–133.4% in the presence of myricetin after oral administration of carvedilol.”
“Concomitant use of myricetin or myricetin-containing dietary supplements with carvedilol will require close monitoring for potential drug interactions.”
“Consequently, the relative bioavailability of carvedilol was increased by 1.17- to 1.85-fold and the absolute bioavailability of carvedilol in the presence of myricetin was increased by 18.1–86.4%.”
“Context: As an inhibitor of CYP2C9, CYP2D6 and P-gp, myricetin might affect the bioavailability of carvedilol when myricetin and carvedilol are used concomitantly for the prevention or therapy of cardiovascular diseases as a combination therapy.”